BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33468799)

  • 1. [Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
    Hamada S; Komatsu S; Shibata R; Konishi T; Matsubara D; Soga K; Shimomura K; Ikeda J; Taniguchi F; Shioaki Y
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):2056-2058. PubMed ID: 33468799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
    Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T
    Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
    Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
    Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
    BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Alsina M; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Hosokawa A; Yalçın Ş; Fujitani K; Beretta GD; Cutsem EV; Winkler RE; Makris L; Ilson DH; Tabernero J
    Lancet Oncol; 2018 Nov; 19(11):1437-1448. PubMed ID: 30355453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
    Maeda F; Gan S; Yamada A; Kajiyama D; Tokitou F; Kawaguchi M; Amagasa H; Motoyama K; Ganno H; Imai K; Ami K; Iida S; Fukuda A; Ando M; Okano Y
    Gan To Kagaku Ryoho; 2021 Mar; 48(3):419-421. PubMed ID: 33790174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
    Shitara K; George B; Taieb J; Sundar R; Fakih MG; Makris L; Benhadji KA; Ghidini M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9361-9374. PubMed ID: 37213030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.
    Giuliani J; Mantoan B; Mangiola D; Muraro M; Napoli G; Tommasi M; Fiorica F; Mandarà M
    Clin Colorectal Cancer; 2024 Mar; 23(1):1-3. PubMed ID: 37932152
    [No Abstract]   [Full Text] [Related]  

  • 11. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
    Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trifluridine/tipiracil in the treatment of gastric cancer.
    Fostea RM; Arkenau HT
    Future Oncol; 2022 Apr; 18(12):1511-1517. PubMed ID: 35081748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
    Koper A; Wileński S; Śledzińska P; Bebyn M; Koper K
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10867-10877. PubMed ID: 37318592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil.
    Michl GM; Vogt FM; Nouriani A; Ladurner R; Kremer M; Reisländer T; Michl M
    Chemotherapy; 2024; 69(1):27-34. PubMed ID: 37336201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
    Mansoor W; Arkenau HT; Alsina M; Shitara K; Thuss-Patience P; Cuffe S; Dvorkin M; Park D; Ando T; Van Den Eynde M; Beretta GD; Zaniboni A; Doi T; Tabernero J; Ilson DH; Makris L; Benhadji KA; Van Cutsem E
    Gastric Cancer; 2021 Jul; 24(4):970-977. PubMed ID: 33713215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
    Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
    Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.
    Aquino de Moraes FC; Dantas Leite Pessôa FD; Duarte de Castro Ribeiro CH; Rodrigues Fernandes M; Rodríguez Burbano RM; Carneiro Dos Santos NP
    BMC Cancer; 2024 Jun; 24(1):674. PubMed ID: 38825703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
    Yoshino T; Uetake H; Funato Y; Yamaguchi Y; Koyama T; Ozawa D; Tajiri M; Muro K
    Jpn J Clin Oncol; 2021 Apr; 51(5):700-706. PubMed ID: 33438718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.